d9c3eecc10
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
- Source: inbox/queue/2026-05-09-pmc12374370-glp1-parkinson-updated-meta-analysis-2025.md - Domain: health - Claims: 0, Entities: 1 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
39 lines
No EOL
1.8 KiB
Markdown
39 lines
No EOL
1.8 KiB
Markdown
---
|
|
type: entity
|
|
entity_type: research_program
|
|
name: MOST-ABLE Trial
|
|
full_name: Oral Semaglutide for Parkinson's Disease Motor Symptoms Trial
|
|
domain: health
|
|
status: active
|
|
---
|
|
|
|
# MOST-ABLE Trial
|
|
|
|
**Type:** Phase 2/3 randomized controlled trial
|
|
**Intervention:** Oral semaglutide 7mg and 14mg daily
|
|
**Population:** n=99 patients with Parkinson's disease
|
|
**Location:** Japan
|
|
**Primary Endpoint:** Motor symptom improvement (MDS-UPDRS Part III)
|
|
|
|
## Overview
|
|
|
|
MOST-ABLE is the first randomized controlled trial testing semaglutide specifically for Parkinson's disease motor symptoms. Unlike prior GLP-1 Parkinson's trials (exenatide, liraglutide, lixisenatide), this study uses oral semaglutide, which has a distinct CNS access mechanism via tanycytes targeting hypothalamus and brainstem regions.
|
|
|
|
## Significance
|
|
|
|
The trial addresses a critical evidence gap: all prior GLP-1 Parkinson's RCTs used older GLP-1 agonists with different CNS penetrance profiles. Exenatide's Phase 3 failure (Lancet Feb 2025) revealed that blood-brain barrier crossing does not guarantee substantia nigra penetrance. Semaglutide's tanycyte-mediated CNS access may provide superior regional distribution, but this remains empirically unproven.
|
|
|
|
## Timeline
|
|
|
|
- **2024** — Protocol published, enrollment completed
|
|
- **Nov-Dec 2025** — Data collection completed
|
|
- **2026** — Results expected (as of May 2026, publication pending)
|
|
|
|
## Context
|
|
|
|
Meta-analysis of 5 prior GLP-1 Parkinson's RCTs (n=708) shows narrow motor benefit (MDS-UPDRS Part III -2.06, 95% CI -4.09 to -0.03) but no functional quality of life improvement. MOST-ABLE results will determine whether semaglutide's distinct CNS access mechanism translates to superior clinical efficacy.
|
|
|
|
## Sources
|
|
|
|
- PMC12374370 meta-analysis (Jan 2025)
|
|
- Session 40 GLP-1 Parkinson's divergence analysis (May 2026) |